Literature DB >> 3024539

Uptake of low density lipoproteins by the hamster lung. Interactions with capillary endothelium.

A Nistor, M Simionescu.   

Abstract

The mechanism by which the circulating low density lipoproteins (LDL) contribute to the lung surfactant cholesterol was investigated by perfusing the hamster lung in situ with LDL either radiolabeled or coupled to gold, or both. Part of [125I]-LDL and [3H]-cholesterol LDL were taken up by a specific process which was time- and concentration-dependent and reached saturation within 20 to 30 min of perfusion. Competition experiments and removal of receptor-bound LDL by heparin suggested that about 50% of LDL uptake is receptor-independent. Experiments using double labeled LDL showed a preferential uptake of 3H-cholesterol versus 125I by the lung both in situ and in vivo. LDL-gold particles (LDL-Au), recirculated through the isolated lung, bound to the endothelial luminal plasma membrane and to features potentially involved in receptor-mediated endocytosis (coated pits, coated vesicles, lysosomelike structures) and in transcytosis (plasmalemmal vesicles). The results suggest that LDL uptake by the lung takes place by both receptor-mediated and receptor-independent mechanisms. Cholesterol may be in part transferred to the lung without the apoprotein moiety; the alveolar capillary endothelium appears to be the first monitor of this complex process.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3024539     DOI: 10.1164/arrd.1986.134.6.1266

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  9 in total

1.  Roles of the Mevalonate Pathway and Cholesterol Trafficking in Pulmonary Host Defense.

Authors:  Kristin A Gabor; Michael B Fessler
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

2.  ATP-binding cassette transporter G1 deficiency dysregulates host defense in the lung.

Authors:  David W Draper; Jennifer H Madenspacher; Darlene Dixon; Debra H King; Alan T Remaley; Michael B Fessler
Journal:  Am J Respir Crit Care Med       Date:  2010-04-15       Impact factor: 21.405

3.  Emerging roles for cholesterol and lipoproteins in lung disease.

Authors:  Kymberly M Gowdy; Michael B Fessler
Journal:  Pulm Pharmacol Ther       Date:  2012-06-15       Impact factor: 3.410

4.  Dyslipidemia induces opposing effects on intrapulmonary and extrapulmonary host defense through divergent TLR response phenotypes.

Authors:  Jennifer H Madenspacher; David W Draper; Kathleen A Smoak; Haitao Li; Gary L Griffiths; Benjamin T Suratt; Martha D Wilson; Lawrence L Rudel; Michael B Fessler
Journal:  J Immunol       Date:  2010-06-25       Impact factor: 5.422

5.  Next stop for HDL: the lung.

Authors:  M B Fessler
Journal:  Clin Exp Allergy       Date:  2012-03       Impact factor: 5.018

6.  Serum Lipoproteins Are Critical for Pulmonary Innate Defense against Staphylococcus aureus Quorum Sensing.

Authors:  Brett C Manifold-Wheeler; Bradley O Elmore; Kathleen D Triplett; Moriah J Castleman; Michael Otto; Pamela R Hall
Journal:  J Immunol       Date:  2015-11-25       Impact factor: 5.422

7.  Novel relationship of serum cholesterol with asthma and wheeze in the United States.

Authors:  Michael B Fessler; Mark W Massing; Brian Spruell; Renee Jaramillo; David W Draper; Jennifer H Madenspacher; Samuel J Arbes; Agustin Calatroni; Darryl C Zeldin
Journal:  J Allergy Clin Immunol       Date:  2009-10-03       Impact factor: 10.793

8.  The Effect of Statins on Blood Gene Expression in COPD.

Authors:  Ma'en Obeidat; Nick Fishbane; Yunlong Nie; Virginia Chen; Zsuzsanna Hollander; Scott J Tebbutt; Yohan Bossé; Raymond T Ng; Bruce E Miller; Bruce McManus; Stephen Rennard; Peter D Paré; Don D Sin
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

9.  Effect of irreversibly glycated LDL in human vascular smooth muscle cells: lipid loading, oxidative and inflammatory stress.

Authors:  Anca V Sima; Gabriela M Botez; Camelia S Stancu; Adrian Manea; Monica Raicu; Maya Simionescu
Journal:  J Cell Mol Med       Date:  2010-12       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.